Neuronetics Inc (STIM) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Neuronetics Inc stock (STIM) is currently trading at $1.40. Neuronetics Inc PS ratio (Price-to-Sales) is 0.67. Analyst consensus price target for STIM is $4.33. WallStSmart rates STIM as Sell.
- STIM PE ratio analysis and historical PE chart
- STIM PS ratio (Price-to-Sales) history and trend
- STIM intrinsic value — DCF, Graham Number, EPV models
- STIM stock price prediction 2025 2026 2027 2028 2029 2030
- STIM fair value vs current price
- STIM insider transactions and insider buying
- Is STIM undervalued or overvalued?
- Neuronetics Inc financial analysis — revenue, earnings, cash flow
- STIM Piotroski F-Score and Altman Z-Score
- STIM analyst price target and Smart Rating
Neuronetics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Neuronetics Inc (STIM) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, revenue growth, institutional own.. Concerns around market cap and return on equity. Mixed signals suggest waiting for clearer direction before acting.
Neuronetics Inc (STIM) Key Strengths (3)
Paying less than $1 for every $1 of annual revenue
Revenue surging 85.70% year-over-year
64.41% held by institutions, strong professional interest
Supporting Valuation Data
Neuronetics Inc (STIM) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Micro-cap company with very limited liquidity and high volatility
Premium pricing at 4.5x book value
Neuronetics Inc (STIM) Detailed Analysis Report
Overall Assessment
This company scores 36/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 3 register as strengths (avg 9.3/10) while 5 fall into concern territory (avg 1.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Revenue Growth, Institutional Own.. Valuation metrics including Price/Sales (0.67) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 85.70%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Book (4.46) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -134.90%, Operating Margin at -11.10%, Profit Margin at -26.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -134.90% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 85.70% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
STIM Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
STIM's Price-to-Sales ratio of 0.67x trades at a deep discount to its historical average of 8.34x (1th percentile). The current valuation is 99% below its historical high of 55.98x set in Aug 2018, and 0% above its historical low of 0.67x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~3.4x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Neuronetics Inc (STIM) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Neuronetics Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 149M with 86% growth year-over-year. The company is currently unprofitable, posting a -26.2% profit margin.
Key Findings
Revenue growing at 86% YoY, reaching 149M. This pace significantly outperforms most MEDICAL DEVICES peers.
Generating 692,000 in free cash flow and 908,000 in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -26.2% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Growth sustainability: can Neuronetics Inc maintain 86%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Neuronetics Inc.
Bottom Line
Neuronetics Inc is a high-conviction growth story with revenue accelerating at 86% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -26.2% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(17 last 3 months)
| Insider | Type | Shares |
|---|---|---|
CHERNETT, JOREY 10% Owner | Buy | +450,000 |
| Insider | Type | Shares |
|---|---|---|
CHERNETT, JOREY 10% Owner | Buy | +607,400 |
| Insider | Type | Shares |
|---|---|---|
MACAN, WILLIAM ANDREW EVP, CLO and CS | Sell | -609 |
Data sourced from SEC Form 4 filings
Last updated: 8:21:39 AM
About Neuronetics Inc(STIM)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
Neuronetics, Inc., a commercial-stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company is headquartered in Malvern, Pennsylvania.